Class Notes (837,538)
Canada (510,303)
Psychology (3,977)
PSYC 3030 (47)
Lecture 3

Week 3

13 Pages
124 Views
Unlock Document

Department
Psychology
Course
PSYC 3030
Professor
Rob Foster
Semester
Winter

Description
Contents PRINCIPLES OF PHARMACOLOGY The same drug can have multiple actions and effects -> multiple ways of producing molecular changes. Specific effects 1. Acts at neurotransmitter binding sites 2. Modifies gating mechanism inside channel 3. Direct interaction with channel protein 4. Stimulates G shich is linked to adenylyl cyclase Nonspecific effects 1. Alters lipid composition 2. Interacts with polar heads of phospholipids 3. Disturbs the relationship of protein in membrane Neurotransmitte Acute cellular Chronic cellular Behavioral effects r effects effects Glutamate Receptor antagonism Memory loss and reduces release Up-regulation of Rebound hyper receptors and excitability of the rebound increase in abstinence syndrome release Extreme hyper Brain damage excitability and massive Ca influx (rebound) GABA Acutely enhances Sedative effects: GABA-induced Cl - anxiety reduction, influx to sedation, hyperpolarize incoordination, memory impairment Neuroadaptive Tolerance and signs decrease in GABA of hyper excitability function without during withdrawal change in receptor (seizures, tremors) number Dopamine Acute increase in Reinforcement transmission in mesolimbic tract Chronic effects show Negative effect as a reduced firing rate, sign of withdrawal release, metabolism Opioids Acute increase in Reinforcement endogenous opioid synthesis and release Neuroadaptive Dysphoria decrease in endorphin levels Site of drug action is not always the site of drug effect E.g.: miosis and mydriasis are controlled by different mechanisms Opiates/opioids acute action  pupil constriction - Atropine, a competitive antagonist for the muscarinic acetylcholine receptor, produces mydriasis because the pupils are no longer capable of constriction and dilation results. - Miosis induced by central (ciliary ganglion) stimulation of parasympathetic input to the iris sphincter muscle, resulting in constriction of the pupil. Similar drug effects can be initiated by different drugs/actions - Nicotinic receptors are found in VTA neurons  when nicotine binds, I causes dopamine release, that is critical for drug reinforcement o Nicotine binds predominantly to nicotinic acetylcholine receptors (nACh) o Release of dopamine in the nucleus accumbens (whih is linked to reward) - Opioids inhibit GABA neurons -> then they stop inhibiting other neurons, leading to more firing and dopamine release. Determinants of drug action 1. Chemical structure of a drug & dose 2. Where the drug acts (target sites) 3. How much drug is free to bind to target sites to elicit drug action (at the same time, the drug is being collected by nonspecific binding, reducing the amount available in the blood to get to the target sites)  Bioavailability. Collectively, these factors constitute the pharmacokinetic component of drug action. 4. In addition to bioavailability, the drug effect experienced will also depend on I) how quickly the drug reaches its target sites, and II) for how long it is available at the target sites Pharmacokinetic factors that determine bioavailability of drugs (1) Drug administration – oral, intravenous, intraperitoneal, subcutaneous, intramuscular, inhalation  determines how quickly and how completely the drug is absorbed into the blood. (2) Absorption and distribution – membranes of oral cavity, gastrointestinal tract, peritoneum, skin, muscles, lungs  because a drug rarely acts where it initially contacts the body, it must pass through a variety of cell membranes and enter the blood plasma (3) Binding – while in the blood, a drug may also bind (depot binding) to plasma proteins or may be stores temporarily in bone or fat, where is inactive. (4) Inactivation – liver  occurs primarily as a result of metabolic processes in the liver. (5) Excretion – intestines, kidneys, lungs, sweat glands, etc. Drug absorption and distribution Two major categories of administration methods: a. Enteral methods – use the gastrointestinal tract; agents are generally slow in onset and produce highly variable blood levels of drug. b. Parenteral methods – include those that do not use the alimentary canal, such as injection, pulmonary, and topic administration. Routes of administration – how much drug reaches its site of action and how quickly the drug effect occurs. It depends on: - Area of absorbing surface - Number of cell layers between site of administration and blood - Amount of drug destroyed by first-pass liver metabolism - Extent of binding to food or inert complexes - Drug concentration Oral administration (PO) – most popular route, the drug must be resistant to destruction by stomach acid and enzymes (for this reason insulin cannot be administered orally). Oral administration produces drug plasma levels that are more irregular and unpredictable and rise more slowly than those produced by other methods of administration. Rectal administration – requires the placement of a drug-filled suppository in the rectum. Intravenous (IV) – most rapid and accurate method, however, the quick onset of drug effect is also a potential hazard. The drug reaches the brain almost instantly, toxic reactions are common, risk of infections. Intramuscular (IM) – advantage of slower, more even absorption over a period of time. Intraperitoneal (IP) – is rarely used with humans, but is the most common route of administration for small laboratory animals. It produces rapid effects, but not as rapid as those produced by IV injection. Subcutaneous (SC) – absorption rate is dependent on blood flow to the site, but is usually fairly slow and steady. Inhalation – absorption is very rapid because the area of the pulmonary absorbing surfaces is large and rich with capillaries. The effect on the brain I very rapid because blood from the capillaries of the lungs travels only a short distance back to the heart before it is pumped quickly to the brain via the carotid artery. Topical – provides local drug effects. Intranasal administration can also have systemic effects. Special injection methods must be used for some drugs that act on nerve cells, because a cellular barrier, the blood-brain barrier, prevents or slows passage of these drugs from the blood into neural tissue. E.g. epidural. - In animal experiences, a microsyringe or a cannula enables precise drug injection into discrete areas of brain tissue (intracranial IC), or into the cerebrospinal fluid-filled chambers, the ventricles (intracerebroventricular ICV). Drug dose Drug dose is expressed in mg of drug/kg of body weight. - More kg = larger volume of body fluids = require more drug - In females, ratio of adipose tissue to body water is greater, so at equivalent dose and kg, drug concentration is higher in females. Drug transport across membranes The molecular characteristics of the cell membrane prevent most molecules from passing through unless they are soluble in fat. Lipid soluble drugs Move through cell membranes by passive diffusion, and the movement across the membranes is always in a direction from higher to lower concentration. The larger the concentration gradient the more rapid is the diffusion.  Partition ratio = concentration of drug in oil / in water. The characteristic that determines oil/water solubility is the extent of ionization of the molecule. Ionization factor Extent of ionization of a drug depends on the electron attraction and repulsion of the various atoms that make up the molecule.  Drugs that are unionized have very little electrostatic charges. This allows them to freely mix with lipid layers that are non polar. These drugs have high partition ratio. o Unionized drugs = lipid soluble drugs  Drugs that are ionized are bound to water molecules by electrostatic attraction and do not readily move from the aqueous to the lipid components of membranes. These drugs have low partition ratio. o Ionized drugs = lipid insoluble drugs  ionization depends on the acidity and the alkalinity of the fluid in which the drug is dissolved. o pKa of a drug = extent of ionization of a drug (pH of the aqueous solution in which that drug would be 50% ionized and 50% unionized) o drugs that are weak acids become more ionized in alkaline environments (less lipid soluble) and become less ionized in acidic environments (therefore more lipid soluble). Passive diffusion Rate of passive diffusion is modulated by: 1. Concentration gradient 2. Blood flow to the absorbing area  if it is very quick, the concentration will be very high all the time; however, if it is slower, the drug will not be removed quickly and the passive diffusion will be slower as well. Effect of ionization on drug absorption a. In stomach acid (pH 2.0) aspirin molecules tend to remain in the non-ionized form  promotes the passage of the drug through the cell walls to the blood (pH 7.4) b. Once they reach the blood, they ionize (more alkaline environment) and are trapped in the blood to be circulated throughout the body. Drug binding 1. Organs 2. Silent receptors (depot binding)  albumin, muscles, bone, fat a. Drug binding occurs at inactive sites, where no measurable biological effect is initiated. Any drug molecules tied up in these depots cannot reach active sites, nor can they be metabolized by the liver. However, the drug binding is reversible, so the drug remains bound only until the blood level drops, causing it to unbind gradually and circulate in the plasm. 3. Receptors Receptors – two general locations I) Embedded in cell membrane – receptors found on the outside of cells that relay information through the membrane to affect intracellular processes. II) In the cytoplasm or in the nucleus – alters cell function by triggering changes in expression of genetic material within the nucleus, producing differences in protein synthesis. Common features of receptors - Ligands = biologically active agents that bind to receptors - Ligand affinity = molecules that have the best chemical “fit”, i.e., the highest affinity, attach most readily to the receptor. - Ligand efficacy = alteration of the 3D structure of the receptor and initiation of intracellular changes; if a ligand is recognized by a receptor but it does not initiate a biological action, it is considered to have low efficacy. - Ligand binding and dissociation = is temporary. When the ligand dissociates from the receptor, it has opportunities to attach once again. - Receptor antagonists = not only do they produce no cellular effect after binding, but by binding to the recepto
More Less

Related notes for PSYC 3030

Log In


OR

Join OneClass

Access over 10 million pages of study
documents for 1.3 million courses.

Sign up

Join to view


OR

By registering, I agree to the Terms and Privacy Policies
Already have an account?
Just a few more details

So we can recommend you notes for your school.

Reset Password

Please enter below the email address you registered with and we will send you a link to reset your password.

Add your courses

Get notes from the top students in your class.


Submit